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Abstract 
Delayed graft function (DGF) and acute rejection (AR) are complications after 
renal transplantation. It is impossible to differentiate between these clinically. 
Renal biopsy is the gold standard for diagnosis but is invasive and associated 
with complications. We aimed to identify early biomarkers, of DGF and AR in 
renal transplantation, which could lead to a diagnostic test that has no morbidity 
or mortality associated with its use. In total 163 from twenty-four patients using 
blood samples over several different pre and post-operative time-points were 
analysed. Plasma was extracted and analysed by 1H nuclear magnetic resonance 
spectroscopy (NMR). Spectra were interrogated using multivariate statistics, 
namely Principal component analysis (PCA) to reveal metabolites whose 
concentration varied as a function of kidney status. High performance liquid 
chromatography (HPLC) was used to validate and analyse molecules seen in the 
NMR studies. Until the third post-operative day, no differences were observed in 
the plasma metabolic profile of patients with DGF or AR in the NMR studies. 
From day four onwards molecules, trimethylamine-N-oxide and creatinine were 
found to vary in concentration across the patient groups in a way that correlated 
with the transplant outcome. In conclusion biomarkers exist in plasma which 
permit the discrimination between patients with DGF and AR, from day four 
following renal transplantation. These biomarkers are accessible, relatively 
non-invasive and without the morbidity associated with biopsy. A combination 
of these biomarkers presents the possibility of the development of a clinical 
diagnostic to improve clinical outcome.  
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1.1 Introduction 
Over the past twenty years there has been a rapid expansion in the techniques 
available to analyse biological systems. Metabolomics is a relatively new term, 
having been coined in 1999 (Nicholson JK, 1999). It is defined as “the 
quantitative measurement of the dynamic multiparametric metabolic response of 
living systems to pathophysiologic stimuli or genetic modification” and is 
concerned with the high throughput identification and quantification of the small 
molecule metabolites in the metabolome (Goodacre R et al., 2004). The 
metabolome is the collection of the complete complement of all low molecular 
weight (<1500 Daltons [Da]) metabolites found in a system (cell, tissue, or 
organism) under a given set of conditions (Goodacre R, 2004; Wishart D, 2007). 
The metabolome constitutes the interaction between small molecules, such as 
metabolic substrates and products, lipids, small peptides, vitamins, and other 
protein co-factors (Ryals J, 2004; Beecher CWW, 2003).  
A summary of metabolomic related definitions is provided in Table 1.1  
 Table 1.1 Definitions related to metabolomics (Dettmer K et al., 2007) 
Metabolite  Small molecules that participate in general metabolic 
reactions and that are required for the maintenance, growth 
and normal function of a cell 
Metabolome The complete set of metabolites in an organism 
Metabolomics Identification and quantification of all metabolites in a 
biological system 
 
!3 
 
Metabolomics is a rapidly expanding area of scientific research and is one of the 
new “omics” joining genomics, transcriptomics and proteomics, in an area of 
science trying to understand global systems biology (Schmidt C, 2004). This 
expansion has been reflected in the number of publications over the last 30-40 
years with a steady increase since the year 2000 (Beecher CWW, 2003; Schmidt 
C, 2004). Further evidence of the rapid growth in the field is the recent launch of 
a dedicated journal Metabolomics (Springer, United Kingdom). 
The profiling of metabolites was first reported in the literature in the 1950s but 
subsequent progress was slow, and only since the turn of the new millennium has 
metabolomics started to become a stand alone scientific entity.  
The recent development of omic technologies and the analysis of the genome, 
transcriptome, proteome or metabolome, for understanding of complex systems 
and diseases at a global level, enable hypothesis generation and have occurred 
predominantly due to improvements in analytical techniques and data handling 
systems (Rochfort S, 2005). Whilst metabolomics is at the endpoint of the 
“omics cascade” and closest to the phenotype, which makes them a more 
appropriate target for phenotype- based research there is still no single-
instrument platform that can currently analyse all metabolites (Dettmer K et al., 
2007), nor is there a standard complete metabolic database. When attaining a 
metabolic profile from a sample for analysis the process focuses on groups of 
metabolites. Often prior to the study the metabolites that may predict outcome 
are unknown and the method is akin to a “fishing expedition”, as opposed to a 
“hypothesis driven” search which involves looking for trends that may foresee a 
result before it occurs. This can lead to problems; as with any high throughput 
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technology, metabolomics can be subject to high rates of false negative or false 
positive results.  
The importance of metabolites in relation to the pathogenesis of disease is only 
just beginning to be fully understood, yet it is well appreciated that metabolites 
serve as markers for both the genome and proteome.!Metabolites are not inert 
and are more than end products of metabolism. The study of single amino acid 
changes in a protein or a single base change in a gene can lead to as much as a 
10,000 fold change in the concentration of certain metabolites (Bory C et al., 
1990). Under toxic stress, cells attempt to maintain homeostasis and metabolic 
control by varying the composition of the body fluids that either perfuse them or 
are secreted by them. This involves the simultaneous adjustment in the 
concentrations of hundreds or thousands of metabolites in order to maintain cell 
characteristics. Metabolites such as citrate, lactate, and glucose can reflect 
situations such as apoptotic alterations, hypoxia and oxidative stress. This 
metabolic adjustment is expressed as a metabolic fingerprint that can be sampled, 
analysed and compared (Lindon JC et al 2004). Some authors (Katzmarzyk PT 
and Janssen L, 2004; Johnson JA, 2006) have also suggested that a large 
proportion of chronic disease, and therefore morbidity, arise from an adverse 
interaction between metabolite and the genome or proteome. Metabolites, such as 
those found in blood or urine or any biofluid contain in principle a 
comprehensive picture of the evolution of a patient’s condition. 
 
 
 
!5 
 
1.2 What Links the “Omics?” 
Although metabolomics invariably deals with molecules less than 1500 Da in 
weight there is crossover in analysis and interaction between metabolomics and 
the better known proteomics and genomics [Figure 1.1]. 
 
 
Figure 1.1 The ‘omics’ family 
Genomics was derived from the term genome, which in turn was derived from a 
combination of the words; gene and chromosome to indicate the complete set of 
chromosomes, and the genes contained in them. The term “omics” has come to 
mean an approach capable of generating a comprehensive data set of whatever is 
being measured, be it transcripts (transcriptomics), proteins (proteomics), or 
metabolites (metabolomics) (Robertson DG, 2005). With these large 
comprehensive data sets correlations are sought with physiological and 
pathological conditions.  It has been commented, that given the large amount of 
money spent on genomics and proteomics over the last decade there has been 
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surprisingly little impact on the numbers of new drugs making it into the clinical 
arena (Stumm G, 2002). A possible explanation for this observation is that 
genomics and proteomics do not provide evidence of endpoint markers for 
disease diagnosis, or evaluation of beneficial or adverse drug effects. With 
metabolomics, the ability to document the metabolites and therefore the 
phenotype, an absolute endpoint, may provide the ultimate diagnostic 
information (Lindon JC et al., 2004). It may well be easier to work from the 
phenotype through to the genotype than to try and speculate the significance of 
thousands of changes in transcript expression (Robertson DG, 2005). 
The fields of proteomics and metabolomics use similar kinds of equipment for 
analysis, predominantly, mass spectrometry (MS) and nuclear magnetic 
resonance (NMR) spectroscopy (Drysdale R and Bayraktaroglu L, 2005). In 
proteomics, problems arise from the sheer number of dynamically fluctuating 
proteins. In metabolomics, the general estimations of the size and number of 
species-specific metabolites are at a preliminary stage (Weckwerth W and 
Morgenthal K, 2005). The number of metabolites present in any given species is 
still unknown and estimates vary from 2000 in humans to up to 200 000 in plants 
(Dettmer K et al., 2007; Fiehn O., 2002).  
All proteins are formed from amino acids that are themselves metabolites. 
Proteins use metabolites for their everyday function in the form of co-factors, 
signaling molecules or stabilizing agents, and when these proteins eventually 
decompose they return to a metabolite form. Proteins require metabolites and in 
return the metabolites require the proteins (Wishart D, 2007).  
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1.3 Analytical Techniques  
In principle, the approach to metabolomics consists of two distinguishable parts: 
firstly, an experimental technique must be used to collect data from obtained 
samples. Secondly, a data processing technique must be applied to the dataset in 
order to sift out areas of interest from the millions of individual datapoints that 
are present. The end goal of the analytical technique being to accomplish a 
complete measurement of the metabolome and its responses to external stimuli 
whatever they may be. 
1.4 Sample Collection 
Metabolites are generally labile species, are chemically very diverse, and often 
present in a wide dynamic range. A major goal of all metabolite-profiling is to 
examine all metabolites within the biological system being sampled. Since body 
fluids such as plasma and urine contain huge numbers of small molecules this 
represents a considerable analytical challenge (Fiehn O, 2002). Indeed prior to 
any investigation careful consideration needs to be given to the type of sample, 
time taken to process, containers used in transit as the choice of vessel for sample 
collection is a particularly important requirement for successful metabolic 
profiling. Different tubes routinely used in the clinical setting contain different 
chemicals within them that can affect the resultant spectra and skew 
interpretation of results (Holland NT et al., 2003).  
At all times it is necessary to reduce as much biological variation that is not 
related to the hypothesis, this is because samples of biofluid can be very sensitive 
to diet, environmental factors, gender and geographical location. 
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Before any metabolites are measured it is important that any metabolic activity is 
stopped as quickly as possible to halt ongoing metabolic activity and reflect 
disease endpoint. With human tissue this can by done by snap freezing in liquid 
nitrogen (Hollywood K et al., 2006). At this point, samples are very stable as 
enzyme activity has stopped, and can be safely stored prior to analysis. Platelet 
or erythrocyte membrane samples may be analysed in other solvent media such 
as non-aqueous media enabling relatively non-water soluble lipid-like 
metabolites to be monitored.  
1.5 Sample Analysis 
There are two main technologies that may be used for analysis of the 
metabolome namely MS and NMR. NMR-based metabolomics has the advantage 
of being: non-destructive; non-selective (i.e. removes bias for a specific 
molecule); cost-effective; fast; and with minimal requirements for sample 
preparation. MS, however, is a much more sensitive technique and therefore the 
concentration detection limit is much lower than NMR (Goodacre R et al., 2004; 
Dettmer K et al., 2007; Dunn WB et al., 2005; Whitfield et al., 2004). MS 
requires a pre-separation technique of the metabolic components using either gas 
chromatography or liquid chromatography. The relative pros and cons of the two 
techniques are summarised in Table 1.2 (Robertson DG, 2005; Claudino WM et 
al., 2007). The reproducibility of both methods is not perfect and can result in 
variability in the data. MS based methods are more prone to this variability 
compared to NMR, mainly to the nature of the instrumentation and because the 
samples require more extensive pre-treatment and preparation. 
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Table 1.2 The pros and cons of mass spectrometry (MS) and nuclear 
magnetic resonance (NMR) in relation to metabolomic studies (Robertson 
DG, 2005; Claudino WM et al., 2007) 
 
Variable NMR MS 
Equipment cost High High 
Maintenance cost High High 
Per sample cost Low High 
Reproducibility (within or across 
labs) 
High Moderate 
Identification of unknown 
metabolites 
Time consuming Can be Fast 
Sensitivity Lower than MS but 
approaches micromolar 
(10-3)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               
Higher than 
NMR 
Quantitation Routine Difficult 
Resolvable Metabolites Possible Possible 
Potential for Sample Bias No Yes 
Data Analysis Automation Some Yes 
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1.5.1 Nuclear Magnetic Resonance Spectroscopy 
NMR is widely used in chemistry and was developed in the 1940s.                                                 
It provides detailed information on the molecular structure of substrates. Its 
application to preclinical and medical imaging only really started in the 1980s as 
technology caught up.  
It works on the basis that certain nuclei possess the property of spin. When 
placed in a magnetic field, these spins align themselves with respect to the 
magnetic field. Application of a radiofrequency pulse inverts the spins to a 
higher energy orientation and the magnetisation of the sample is deflected away 
from the direction of the magnetic field. When the radiofrequency (rf) is 
switched off, the spins undergo relaxation to their original lower energy 
orientations. During these processes a detectable NMR signal is produced that 
can be analysed with the aid of a computer in the form of readable spectra. Each 
molecule results in a set of lines in the spectrum, the positions of which 
(chemical shift) depends on chemical environment of the nuclei being observed 
[Figure 1.2] (Turner E et al., 2007). The area under the peak (any line for a 
nucleus from a particular molecule) is proportional to the concentration of that 
molecule present in the solution. Nuclei such as 1H, 13C, 15N and 31P may be 
observed but 1H is the most sensitive (non-radioactive) NMR nucleus and thus 
dominates NMR-based metabolomic studies.  
The NMR spectrum of most metabolites has been analysed and hence it is 
possible to interpret new!spectra on the basis of available data (Claudino WM et 
al., 2007; Griffin JL, 2004). If signals arise which have not previously been 
reported then other NMR experiments may be employed to unambiguously 
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assign these and thereby identify a new metabolite. Typically spectra of biofluids 
such as urine and plasma contain thousands of signals. With blood plasma and 
serum, protein and lipoproteins signals to the 1H NMR spectrum and display 
broad lines, with sharp peaks from small molecules superimposed on them 
(Nicholson JK et al, 1995). Combinations of radiofrequency pulses maybe 
applied to remove these broad signals. Difficulties do occur not only in 
practicality but also interpretation of data. For example, the main component of 
any biofluid is water, which produces an NMR peak so huge that it can obscure 
other molecular information and cause dynamic range problems in the NMR 
detector (Lindon et al., 2004). Suppression techniques are possible to remove the 
water signal which does not interfere or destroy the sample. This is achieved by 
selective irradiation of the water signal with a weak rf field.  In addition 
difficulty can also occur with visualization of low molecular weight metabolites 
in serum or plasma which can be obscured by the broad envelope of high 
molecular weight resonances of plasma proteins such as albumin (Lindon, et al., 
2004).  
Automatic sample preparation for NMR spectroscopy, is feasible. D2O is added 
to act as a magnetic lock with a buffer solution to the biofluid and standard NMR 
spectra can take up to a few minutes to acquire. Using robotic flow injection 
methods, this process allows for larger and quicker throughput of samples. In this 
study a more conventional approach using 5mm diameter NMR capillary tubes 
loaded individually were used.  
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Figure 1.2 1H-NMR Spectrum Section of a plasma 1H-NMR spectrum ala = 
alanine, ile = isoleucine, lys = lysine, met = methionine, thr = threonine, tyr = 
tyrosine, val = valine (Turner E et al., 2007) 
 
 
 
Lactate!
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1.5.2 Mass Spectrometry 
MS is widely available and extensively used and is the standard technique in the 
pharmaceutical industry enabling identification and quantification of drug 
metabolites. MS offers high selectivity and sensitivity (Dettmer K et al., 2007) 
and molecular formulae determination via accurate mass measurements (Dunn 
WB et al., 2005). This makes it an incredibly powerful tool for analysis of large 
numbers of metabolites (Whitfield PD et al., 2004). MS based techniques are 
intrinsically more sensitive than NMR but usually require a sample preparation 
step, which unlike NMR can cause metabolite losses, and based on the sample 
introduction system and the ionization technique used, specific metabolite classes 
may be discriminated against (Dettmer K et al., 2007). Differing types of MS 
exist, with their varying advantages and disadvantages.  Ion suppression and 
matrix effects can lead to difficulties in detecting certain compounds. These 
problems can be overcome by coupling a chromatography system to the mass 
spectrometer. The chromatographic step is able to reduce the number of 
competing analytes entering the mass spectrometer in addition to separating 
complex mixtures of metabolites. Derivatisation is required first in order to 
reduce the polarity of the analytes and enable chromatographic separation. 
(Griffin JL, 2004). As a result, liquid chromatography–MS is increasingly being 
used to profile low-molecular-weight metabolites (Pham-Tuan H et al., 2003; 
Plumb RS et al., 2002; Idborg-Bjorkman et al., 2003).Gas chromatography-MS 
is also growing in popularity for the profiling of volatile compounds (Dunn WB, 
2008; Lenz ME & Wilson ID, 2007) This could be deemed a disadvantage, as 
most biofluids and tissue are involatile. Therefore treatment of samples needs to 
be undertaken to convert samples into volatile substances.  
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1.6 Statistical Analysis 
Generally it is necessary to use data reduction and pattern recognition techniques 
in order to access the latent biochemical information present in the spectra and 
detect meaningful correlations once the data have been collected, as so much 
information is collated (Lindon et al., 2004). Metabolomic studies result in 
complex multivariate data requiring a statistical approach to its analysis. 
Chemometrics is the term ascribed to data reduction and pattern recognition 
applied to chemical numerical data such as used in metabolomics. The aim being 
to assign and classify the spectral peaks, thus being able to identify data, which 
may contribute to a clinical condition. Chemometrics has been used to analyse 
“omic” data in other applications (Jellum E et al., 1981; Jiye A et al., 2005; 
Robertson DG et al., 2000). It affords a well established, robust method of 
handling complicated data to give interpretable outputs. The most commonly 
used statistical approach at present is that of principal components analysis 
(PCA). In its simplest application to NMR data analysis, PCA requires the 
spectrum to be divided into many equally spaced regions (binning) and the area 
of the signal in each of these regions measured. Each region or ‘bin’ is between 
0.01 to 0.04ppm. The bin is then interpreted for each clinical case. The regions 
with the biggest variation in area are likely to report of the status of the patient 
(healthy/unhealthy) and in this way provide a clinically useful biomarker of the 
condition (Dettmer K et al., 2007). PCA is an unsupervised statistical method 
which means that there is no knowledge of group/class of individual samples 
prior to analysis of the samples. The combination of NMR with statistical data 
analysis allows the measurement and interpretation of hundreds of metabolites, 
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quickly, easily and inexpensively (Dunn WB, 2005; Wishart D, 2006; Wishart D, 
2005) [Figure 1.3].  
Comparison of disease processes using chemometrics is to identify either a 
control group or compare different outcomes in patients with the disease. Hence 
in disease modeling a one-class or two-class system can be used. 
One class: Only outcomes of disease define a group as patient group and control 
samples are very heterogeneous (gender, age, diet, lifestyle, disease process) 
Two class: Control group and disease group define two separate classes 
There is a limitation to the process in that it is rare for a peak not to overlap with 
another peak, thus it can be difficult to assign metabolites to overlapping peaks. 
Work is being done to address this problem in the form of library spectra 
(Wishart D, 2008), 2D NMR (Van QN et al, 2008) and statistical correlations 
(Sands CJ et al, 2009). 
There are other methods also available for data reduction. Genetic algorithm 
aligns the peaks in automatically selected segments in each spectrum to the 
corresponding peaks in a preselected reference spectrum. A disadvantage to this 
process is that the reference spectrum cannot account for loss or appearance of 
new peaks (Forshed J et al., 2003). Statistical heterospectroscopy (SHY) allows 
data co-analysis and rapid structural information form metabolites by direct 
comparison between NMR and MS signals (Crockford DJ et al., 2006). 
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Figure 1.3 Data Reduction “binning” of 1H NMR Spectra and the PCA 
Scores Plot from such data    
 
1.7 Applications 
Whilst still in its infancy, metabolomics is beginning to define its importance in 
the role of future medical advances.!Omics technologies are currently used in two 
closely linked areas: biomarker detection and the elucidation of pathophysiologic 
processes to isolate novel therapeutic targets.  
Some important considerations include: 
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1. Over 95% of all diagnostic clinical assays look for small molecules (Tietz 
NW, 1995)  
2. 89% of known drugs are small molecules (Drugbank)  
3. 50% of all drugs are derived from pre-existing metabolites (Mahido et al., 
1998)  
4. 30% of identified genetic disorders involve diseases of small molecule 
metabolism (Hamosh A et al.,  2002)  
In the clinical setting, metabolomics can be used to test cohorts of patients with 
certain pathologies and compare their metabolic profile with a “normal” control 
cohort or to compare the metabolic profile within disease groups. This is known 
as metabolic fingerprinting. A number of complex diseases, such as 
atherosclerosis, type 2 diabetes mellitus and cancer (Wishart D, 2007), may 
result from a chronic imbalance of normal metabolism. Therefore, metabolomic 
based approaches may be of use in identifying surrogate biomarkers of 
pathological states (Whitfield PD et al., 2004). Initially in this approach the 
intention is not to identify each observed metabolite, but to compare patterns or 
‘‘fingerprints’’ of metabolites that change in response to disease, toxin exposure, 
environmental or genetic alterations (Dettmer K et al., 2006). At present 
metabolic fingerprints have been reported for some disease states which include; 
pre-eclampsia (Claudino WM et al., 2007) motor neurone disease (Rozen S et 
al., 2005), Alzheimer’s (Han XM, et al., 2002), coronary artery disease (Sabatine 
MS, et al., 2005), breast cancer (Fan X et al., 2005), ovarian cancer (Odunsi K et 
al., 2005) and hepatic cancer (Yang J, et al., 2004). 
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1.7.1 Toxicology 
Currently in the field of toxicology, NMR and MS have been used to assess the 
health risk of particular toxins/drugs and identifying metabolic differences in 
experimental animals and humans [Table 1.3] (Beckwith-Hall BM et al., 1998; 
Nicholson JK & Wilson ID, 1989; Robertson DG, et al., 2000; Lindon JC, et al., 
2000; Bairaktari E, et al., 1998). The administration of a drug generally induces a 
series of metabolic events many in a time dependent manner, analysis of which 
can provide insight to toxicology/efficacy of the drug Nicholls AW, et al., 2001; 
Waters NJ et al., 2002; Lenz EM, et al., 2004; Lindon JC, 2004) 
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Table 1.3. Metabolic markers associated with toxins as determined by 
metabolomic analysis (Beckwith-Hall BM et al., 1998; Nicholson JK & Wilson 
ID, 1989; Robertson DG, et al., 2000; Lindon JC, et al., 2000; Bairaktari E, et 
al., 1998) 
Toxin Target organ/toxicity 
type 
Associated biomarkers 
Amiodarone  Phospholipidosis (lung) ↑Phenylacetylglycine,!
↑DMG 
a-
Naphthylisothiocyanate 
(ANIT)  
Liver (cholestasis) ↑acetate,!↑bile acids, 
↓citrate,!↑glucose,!
↓hippurate,!↓2-
OG,↓succinate,!
Chloroquine  Phospholipidosis & liver 
necrosis 
↑Phenylacetylglycine, 
↑DMG 
Ethionine  Liver ↑glucose,!↓2-OG,!↑taurine 
Galactosamine  Liver (hepatitis like 
lesion) 
↑acetate,!↑betaine,!↑bile 
acids,!↑creatine,!
↓hippurate,!↑organicacids,!
↑taurine, ↑urocanic acid, 
↓2-OG, ↓succinate!
!20 
 
Lead acetate Liver/lung/kidney ↑acetate,!↑creatine,!
↓citrate,!↑glucose,!
↓hippurate,!↑lactate, ↓2-
OG, ↑N-acetyls,!
↓succinate,!↑taurine 
Paraquat  Kidney & lung ↑amino acids,!↓citrate 
↓creatinine,!↑glucose,!
↓hippurate, ↑lactate & 
organic acids,!↓valine 
Puromycin 
aminonucleoside  
Kidney (glomerulus & 
proximal tubular) 
↑acetate,!↑alanine,!
↓citrate, ↑creatine,!
↑formate,!
↑glucose,↑macromolecules 
(proteins and lipids),!↓2-
OG ,↑taurine, ↑TMAO!
Sodium chromate  Kidney (S1 proximal 
tubular) 
↓citrate,!↑glucose, 
↓hippurate, ↓2-OG!
Sodium fluoride  
 
Kidney (proximal 
tubular) 
↑acetate,!↑amino acids,!
↓citrate!↓creatinine, 
↑glucose, ↓hippurate, 
↑organic acids,!↓2-OG,!
↓succinate, ↑threonine 
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1.7.2 Markers of Disease 
Clinical medicine strives for non-invasive biomarkers that can diagnose 
clinically relevant processes. Biomarkers have a variety of functions, from 
screening to diagnostic to prognostic. As many diseases are indeed a result of 
metabolic disorders, it makes a great deal of sense to measure metabolites 
directly. The value of the glucose stick in diabetes or urine tests for the diagnosis 
of pregnancy show the worth of such simple bedside tests. Therefore a very 
active area of research within metabolomics is that of discovering which 
metabolites are indicative of disease (Hollywood K et al., 2006). The advantages 
of metabolomics in revealing a biomarker are shown in [Table 1.4] (Gwinner W, 
2007).  
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Table 1.4 Advantages of metabolomics in identifying non-invasive 
biomarkers (Gwinner W, 2007). 
Sampling 
Easy access to samples – blood, urine, tissue biopsy  
Repeatable/serial sampling possible 
Marker stability– samples can be stored for long periods 
Analysis 
Reproducible process  
Robustness against interfering substances in the sample – disease context specific 
Explanatory power 
Potential for good specificity and sensitivity – established in literature  
 
Some biomarkers have already been identified. Sanins et al. identified taurine a 
metabolite specific to the liver as a marker of disease. They found that raised 
urinary levels of taurine were associated with necrosis and fatty liver. These 
results correlated with routine blood investigations (Sanins SM et al., 1990). 
Liver dysfunction was also coincident with the appearance of certain types of 
bile acids present in both serum and urine. Beckwith-Hall et al. found that on 
ingestion of liver toxins, certain metabolites were present in high concentrations 
such as cholic, glycocholic, and taurocholic acids (Beckwith-Hall BM et al., 
1998). 
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Gartland et al also observed changes in taurine concentrations. They found that 
following exposure to hydrazine, taurine, citrate and lactate levels were affected 
Gartland KPR et al., 1991). Nicholson et al. identified succinate, glycine, and 
dimethylamine in the blood that were found to be indicators of kidney damage 
(Nicholson JK, et al., 2002). Measurement of urine metabolites has proven to be 
a good marker of kidney damage due to the nature of where urine is derived. 
Anthony et al. and Gartland et al. found metabolites such as glucose, lactate, 
alanine, lysine, glutamine, glutamate, and valine to be present in abundance 
when damage to the proximal tubule of the kidney has occurred. This is due to 
the inability of the damaged kidney to filter metabolites present in the blood 
(Anthony ML, et al., 1994; Gartland KP, et al., 1989; Gartland KP, et al., 1989). 
The main concern in the area of biomarker identification from initial studies is 
that the same metabolites (2-oxoglutarate, acetate, citrate, creatine, creatinine, 
glucose, hippurate, lactate, succinate, taurine and trimethyl amine/trimethyl 
amine oxide (TMA/TMAO) (Robertson DG, 2005) are often present in response 
to drug administration, regardless of the nature of the drug, i.e. different drugs 
often result in similar metabolic profiles when analysing samples such as urine 
(Anthony ML et al., 1994; Holmes E, et al., 1992; Nicholls AW, et al., 2001; 
Robertson DG, et al., 2000). Importantly however, not all these molecules 
materialise in response to every toxicant nor do they appear in the same 
concentrations.  
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1.7.3 Transplantation 
In the field of solid organ transplantation some of the early metabolomic studies 
have looked into primary non-function, delayed graft function and acute 
rejection.  There is currently no single test to differentiate these pathologies. 
Some of the metabolite findings already observed in the field of transplant are 
summarised in Table 1.5 (Wishart D, 2005). 
 In the field of hepatic transplantation, the widening of indications for liver 
transplant coupled with the shortage of donors, has lead to the increased 
utilisation of marginal grafts, which have higher rates of non-function and graft 
failure (Vilca Melendez H, et al., 2000; Duarte IF, et al., 2005; Serkova NJ, et 
al., 2007a). The need for early diagnosis in these settings is becoming more 
apparent. The inability to diagnose primary graft non-function in a liver 
transplant patient at an earlier stage than is possible with currently available 
methods has far reaching implications. A delay in diagnosis can often mean that 
a patient is too ill for re-transplantation, whereas earlier detection within two to 
three hours of the implantation may result in better patient outcomes.  
Serkova et al. reported on the use of metabolic profiling in a single patient who 
was re-transplanted successfully 8 days after the initial graft, which failed due to 
portal vein and hepatic artery thrombosis. They used NMR as a means of 
profiling the patient’s blood: pre-operatively; 2 hours; 24 hours; and 48 hours 
post-operatively. Distinctly different profiles between the first unsuccessful and 
the second successful transplant were demonstrated. Variation was seen between 
the two operations in lactate, uric acid, glutamine, methionine and citrate, 
changes that were seen as early as two hours post operation. The patient’s 
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metabolic profile following the successful transplant was found to be comparable 
with that of 5 healthy volunteer controls (Serkova NJ, et al., 2007a). 
Table 1.5. Summary of metabolite measurement in organ transplantation or 
dysfunction (Wishart D, 2005) 
 
Organ Condition Metabolites Increased Metabolites 
decreased 
Kidney 
(Human) 
Graft dysfunction TMAO, dimethylamine, 
lactate, acetate, succinate, 
glycine, alanine 
 
Kidney 
(Rat) 
Graft dysfunction 
or reperfusion 
injury 
TMAO, dimethylamine, 
lactate, acetate, succinate, 
glycine, alanine 
 
Kidney 
(Rat) 
Reperfusion 
injury 
(ischaemia) 
TMAO, allantoin  
Kidney 
(Human) 
Acute rejection  Nitrates, nitrites, 
nitric oxide 
metabolites (urine) 
Liver 
(Human) 
Reperfusion 
injury 
Lactate, pyruvate, 
glycerol, alanine, 
glutamate, GABA, 
Arginine <19hrs 
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taurine, arginine >19hrs 
Liver 
(Rat) 
Reperfusion 
injury 
Citrate, succinate, ketone 
bodies (GOOD function) 
Citrate, succinate, 
ketone bodies 
(POOR function) 
Liver 
(Human) 
Ischaemia Methylarginine, 
dimethylarginine 
 
Liver 
(Human) 
Graft dysfunction Glutamine Urea 
Liver 
(Human) 
Post-transplant Phosphatidylcholine (bile)  
 
In renal transplantation, current monitoring of transplant recipients relies on 
technologies that have been in the clinical domain for many years, including 
measurement of serum creatinine levels, total urine output and blood pressure. 
Whilst identifying renal dysfunction, these tests do not provide sufficient 
specificity or sensitivity to determine the cause of impaired function and 
therefore may not allow appropriate and timely intervention. This is due to the 
presence of confounding factors such as hypertension, infection and 
immunosuppressive medications. In such cases, patients often require invasive 
biopsies and thus the definitive diagnosis of delayed graft function or acute 
rejection may be delayed (Wishart D, 2006; Gwinner W, 2007; Veronese FV, et 
al., 2005; Hauert, et al; 2000). Transplant biopsies are currently the only reliable 
!27 
 
method of diagnosing the aetiology of transplant dysfunction, however they are 
not without complication and do present a risk both to patient and graft (Rush D, 
et al., 2000).  
Rush et al. in 2000 examined the role of NMR in the identification of acute 
rejection following renal transplantation in patient urine samples (Rush D, et al., 
2000). They reported 93% sensitivity and 96% specificity for the determination 
of acute rejection whilst the process was still at a subclinical level and therefore 
before the traditional methods of diagnosis. They predicted acute rejection three 
days earlier than with traditional methods of measuring serum creatinine 
allowing earlier treatment and improved long-term outcomes. The name of the 
metabolite identified was not revealed in the publication. The importance of early 
diagnosis of acute rejection at a preclinical level had previously been identified 
in a randomised study by the same group (Rush D, et al., 1998). They found 
early corticosteroid treatment of patients diagnosed with subclinical rejection 
based on invasive biopsy had better long-term outcomes. They showed a 
decrease in early and late clinical rejection, a lower serum creatinine at twenty-
four months and improved long-term graft function in renal transplant patients 
subjected to protocol biopsies.  
Foxall et al looked at patients with a diagnosis of either acute rejection or 
cyclosporin nephrotoxicity by analysing urine (Foxall PJ, et al., 1993). A 
significant clinical problem with transplant patients is differentiating between 
patients undergoing graft rejection and those suffering from cyclosporin toxicity. 
NMR was shown to clearly demonstrate and differentiate when a patient was 
undergoing graft rejection as apposed to cyclosporin nephrotoxicity (Foxall PJ, et 
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al., 1993). They noted a statistically significant increase in Trimethyl-N-oxide in 
those with graft dysfunction.  
1.7.4 Oncology 
In the vast area of oncology work is still surprisingly in its early stages. Yet 
cancer metabolism represents a field ideal to metabolic profiling because of the 
way its metabolism differs substantially from normal cells, especially that of the 
glucose and phospholipid metabolism (Serkova N, et al., 2007b). 
Conventional treatment has a somewhat blunderbuss approach with treatment 
strategy based on tumour size and stage. A more individual approach targeting 
specific antigens and antibodies has led to the development of specific 
biomarkers to assess treatment progress. Linking metabolic profiles to cancer 
depends heavily on the analytical instruments available since in the 
aetiopathogenesis of cancers, abnormalities in gene expression, protein 
expression and biochemical pathways often coexist (Schmidt C, 2004). 
Traditional approaches using single molecule markers are often associated with a 
low predictive value (Foxall PJ, et al., 1993). Current markers identified are 
shown in Table 1.6  
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Table 1.6 Oncological metabolite markers 
(Marcotte EM, 2001; El-Sayed S, et al., 2002; Moreno A, et al., 1998; Ben-
Yoseph O et al., l1993; Beckonert O, et al., 2003; Howells SL, et al., 1992; 
Carmichael PL, et al., 1998; Chen JH, et al., 2001; Millis K, et al., 1999; Jordan 
KW & Cheng LL,!2007)  
Metabolite Tumour Association 
Taurine Increased in squamous cell carcinoma, 
prostate cancer and liver metastases  
Alanine Increased in astrocytomas, gliomas, 
meningiomas and hepatomas 
Myo-inositol Increased in colonic and ovarian 
cancer. Decreased in breast cancer 
Choline Varying levels in hepatomas, prostate 
and brain tumours 
 
NMR is able to assess and quantify all upregulated glycolytic metabolites. Genes 
known to be associated with cancer p53, c-MYC and HIF-1 all cause an increase 
in glucose metabolism. Metabolic profiling can assess this increase in glucose 
uptake via the tumour cells (Matoba S, et al., 2006; Kim JW, et al., 2006; Shim 
H, et al., 1997) 
Griffiths and Stubbs used NMR spectroscopy to measure metabolite changes in 
mouse-derived tumour cells that were deficient in the transcription factor, 
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hypoxia-inducible factor-1 (HIF-1) (Griffiths JR, et al., 2002). HIF-1 has been 
widely shown to play a direct role in accelerating tumour growth. They found 
that adenosine triphosphate production was impaired in HIF-1 deficient tumour 
cells. The spectra also revealed lower concentrations of glycine, betaine and 
some choline based metabolites. These metabolites are required for purine 
synthesis thus demonstrating possible avenues for future drug therapies in the bid 
to stop tumour growth (Griffiths JR, et al., 2002; Griffiths JR, et al., 2003).  
Sitter et al. studied patients with breast cancer and looked at 88 tumour samples 
and 18 tissue samples from adjacent non-tumour tissue (Sitter B, et al., 2006). 
With the use of high-resolution magic-angle spinning (HR-MAS) magnetic 
resonance spectroscopy they compared the fingerprints obtained from the two 
types of tissue. The concentrations of glycerophosphocholine, phosphocholine, 
and choline signals were recorded. They reported 82% sensitivity and 100% 
specificity. The study demonstrated that tumoral tissues when assessable by HR-
MAS MR spectroscopy differed in their metabolic content from their benign 
counterparts (DeVita VT, et al., 2005) 
Odunsi et al compared 38 patients with epithelial ovarian cancer with 12 patients 
with benign ovarian cysts and 53 healthy women. Clear differentiation was 
observed between those with cancer and those without, although the nature of the 
metabolites giving rise to the discrimination has yet to be determined (Odunsi K, 
et al., 2005). 
Prostate cancer has a high incidence in men over 50 years old and current tests 
such as prostate specific antigen (PSA) and digital rectal examination (DRE) are 
not sufficiently specific. PSA although only seen in relation to prostatic 
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pathology, can be elevated in benign conditions such as benign prostatic 
hyperplasia and prostatitis. Abnormal PSA and DRE findings are only accurate 
for cancer in between 25-50% of cases (Jordan KW, et al., 2007). This can often 
lead onto prostate core biopsies, an invasive procedure not without its own 
morbidity, but nevertheless the gold standard in this field of cancer diagnosis. 
Sheidler et al. combined magnetic resonance spectroscopic imaging with 
traditional techniques of magnetic resonance imaging. This involved quantitative 
detection of choline, citrate and creatine via echo delay. They demonstrated an 
increase in sensitivity and specificity for the diagnosis of prostate cancer of 95% 
and 91% respectively, compared to established sensitivities and specificities of 
between 60-75% with current tests. The process noted that the three metabolites 
appeared in different ratios when compared between benign and malignant 
conditions (Sheidler J, et al., 1999) 
Excellent discrimination in lung cancer patients has been seen by Vautz et al. 
Analysis of 36 lung cancer patients versus 54 healthy controls using metabolic 
profiles of breath showed correct classification in 99% of the patients. The 
process involved using Ion mobility spectrometry (IMS) coupled to a multi-
capillary column alongside an integrated medical software system for data 
processing (Vautz W & Baumbach JI, 2008). 
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1.7.5 Coronary Heart Disease 
Brindle et al. used NMR analysis of serum to differentiate patients with triple 
vessel coronary heart disease from angiographically normal subjects (Brindle JT, 
et al., 2002).  They were able to distinguish not only the presence of disease but 
also the severity of the coronary disease on the basis of NMR studies. Their 
study differentiated greater than 90% of patients with three vessel disease over 
patients with normal angiograms. From the study it was also possible to diagnose 
the severity of coronary stenosis. However the results of this work have been 
questioned (Kirschenlohr HL. et al., 2006). Acute events such as myocardial 
infarctions are by their nature unpredictable which precludes prior blood 
sampling for predictive purposes. The atherothrombotic plaques involved in 
coronary artery disease are varied in their proportions which may influence 
plasma biochemistry.   
1.8 The Future  
Metabolomics is a burgeoning science, usually combining high resolution NMR 
or MS with pattern recognition strategies to rapidly and accurately diagnose the 
metabolic status of the sample being studied. It has developed considerably in the 
last decade and is now recognized as an independent and widely used technique, 
as well as a proteomics-complementing technology (Weckwerth W, et al., 2003) 
Metabolomics has the ability to evaluate onset, duration, severity and organ 
specificity of a disease or condition from easily available samples. As knowledge 
in this field improves, along with the evolution of the Human Metabolome 
Project (Wishart D, 2007) , the discovery of new metabolites and their interaction 
with the human genome and proteome will allow further advances in: drug 
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manufacture with enhanced drug targeting; development of biomarkers; and a 
better understanding of diseases processes. It has already been adopted by a 
number of pharmaceutical companies in their drug development initiatives 
(Lindon JC, et al., 2004). 
With regards to its clinical potential, metabolomics allows diagnosis of 
pathological conditions through identification of disease specific fingerprints, 
and changes in such profiles will assist in assessing disease progression and 
monitoring treatment (Turner E, et al., 2007). The technology will also be able to 
predict drug toxicity and response following medical intervention such as 
administration of chemotherapy to oncology patients.  
Metabolomics can provide new biomarkers, and with its ability to measure more 
than one metabolite at anyone time, this process will surely be more predictive 
than traditional single marker testing. Over time a powerful list of diagnostic 
markers will evolve, which can be measured using high-throughput assays 
enabling earlier diagnosis and quicker more patient specific treatment.  
1.9 Objectives of This Project 
The purpose of this study is to assess the metabolic activity of patients 
undergoing renal transplantation. Using NMR technology the study aims to 
analyse those patients who in the post-operative period develop acute rejection, 
delayed graft function or have no graft dysfunction and have primary function. 
The aim being to find a non-invasive biomarker that may predict graft outcome 
with the sensitivity and specificity of the current gold standard, a renal biopsy, 
but without the associated complications.    
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Chapter 2 
1H NMR Spectroscopy of Plasma of Renal Transplant Patients 
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2.1 Background 
The clinical course immediately after renal transplantation is varied. Differential 
diagnosis of a graft dysfunction includes AR, acute tubular necrosis (ATN) 
manifesting as DGF, and calcineurin inhibitor (CNI) toxicity. All these can also 
co-exist and contribute to graft dysfunction. Clinical and laboratory findings can 
often be unhelpful and make differentiation between pathologies difficult. 
Reduced urine output, rising serum creatinine levels, hypertension, graft 
tenderness and peripheral oedema (Wishart, 2006) are non-specific diagnostic 
markers. The gold standard is a histological diagnosis obtained from renal 
biopsy. Invasive biopsies are not without their risks. Complications include 
haematuria (35%), haematoma (65%), arteriovenous malformation (AVM), and 
injury to bowel. Whilst most biopsies are asymptomatic, transfusion is required 
in less than 1%, some of these requiring re-exploration (0.3%) and renal loss 
occurs in less than 0.1% of cases. Loss of life is reported but is extremely rare 
(Wishart D, 2006; Hergesell O, et al., 1998; Parrish AE, 1992; Whittier WL & 
Korbet SM, 2004; Lin WC, et al., 2006; Al Rasheed SA, et al., 1990). AR is a 
key factor in long-term graft function and survival in renal transplant patients. 
Timely detection and treatment of rejection is therefore, an important goal in 
post-transplant surveillance (Hergesell O, et al., 1998). Extensive effort has been 
directed towards developing a non-invasive test, which remains as specific and 
sensitive as a biopsy but can be used in the immediate postoperative period 
without risk of injury to patient or transplant, for monitoring of AR (Wishart D, 
2006; Gwinner W, 2007; O’Riordan E, et al., 2004; Clarke W, et al., 2003; 
Wittke S, et al., 2005).  
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Work in this field has concentrated on blood, urine and individual immune and 
injury markers therein. Potential markers identified have included neopterin 
(Carlson IH, 1992), sCD30 (Pelzl S, et al., 2003), monokines induced by IFN-
γ(MIG) (Hauser IA, et al., 2005) and mRNA for perforin granzyme B 
(Vasconcellos LM, et al., 1998) but none of these are in current clinical use.  
We describe in this chapter a NMR spectroscopy-based metabolomics approach 
to the analysis of plasma which has permitted the identification of small 
molecule (metabolite) biomarkers which could act as diagnostics of DGF and 
AR. NMR allows for minimal sample preparation, non-destructive analysis and 
can identify molecules at millimolar concentration. Such hypothesis generating 
metabolomic studies have been performed in the clinical setting previously; in 
transplantation (Serkova NJ, et al., 2006), pre-eclampsia (Turner E, et al, 2007), 
motor neurone disease (Rozen S, et al., 2005), Alzheimer’s (Han XM, et al., 
2002), coronary artery disease (Sabatine MS, et al., 2005), breast cancer (Fan X, 
et al., 2005), ovarian cancer (Odunsi K, et al., 2005), hepatic cancer (Yang J, et 
al., 2004), nephrotoxicity in animal models (Boudonck KJ, et al., 2009), and 
indeed in renal transplantation (Wishart DS, 2005; Hauet T, et al., 2000). In this 
study analysis of 24 patients’ plasma over several post-operative time points by 
proton (1H) NMR spectroscopy has revealed biomarkers present in all classes of 
graft outcome, but their concentrations vary in a graft-status-dependant manner 
such that it is possible to differentiate between DGF, AR and PF from day four 
post-operation. These biomarkers may provide a diagnostic that could aid post-
operative management of renal transplant patients.  
The following chapter focuses on the analysis of plasma of 24 consecutive 
patients, who underwent renal transplantation, using 1H NMR spectroscopy. 
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Samples were taken at nine separate time points where possible. Pre-operatively, 
one to ten minutes post reperfusion, two hours post operation and post-operative 
days, one, two, three, four, five and seven. In some cases nine blood tests were 
not possible per patient if haemolysis of the sample or a delay of greater than one 
hour from patient’s blood test to freezer occurred.  
 
2.2 Patient Selection 
Twenty-four consecutive patients undergoing renal transplantation who were 
admitted to St James’s University Hospital a part of The Leeds Teaching 
Hospitals Trust were recruited into the study. Table 2.1 presents the donor and 
recipient demographics. 
For the purposes of this study patients were divided into three groups according 
to clinical outcome. 
1. Primary function (PF) 
2. Delayed graft function (DGF) 
3. Acute rejection (AR) 
 
If a patient had both DGF and AR, or PF and then AR they were assigned to the 
group with AR. DGF was defined as the need for dialysis in the first week post-
renal transplantation. Diagnosis of DGF or AR was based on histology from a 
biopsy. All biopsies were performed between days six and nine. No patient in 
this study had biopsy proven CNI toxicity. Demographics are shown in Table 
2.1. 
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Table 2.1 – Recipient and Donor Demographics 
Patient Recipient 
Age (yrs) 
Recipient 
Gender 
Aetiology  
of renal failure 
Donor 
Age  
(yrs) 
Type of donor Cause of donor 
death 
HLA Induction 
Agent 
Immuno CIT 
(mins) 
WIT 
(mins) 
Biopsy 
Proven 
DGF 
Biopsy  
Proven  
AR 
1 76 M Unknown 78 Deceased 
donor 
Skull fracture 1:1:1 Bas + MP Tac + 
MMF 
1060 35 N N 
2 55 M Autosomal 
dominant 
interstitial nephritis  
44 Deceased 
donor 
Intracranial 
haemorrhage 
1:1:1 Bas + MP Tac + 
MMF 
957 30 N N 
3 52 M Fanconi’s 59 Deceased 
donor 
Cerebral infarct 1:1:1 Bas + MP Tac + 
MMF 
750 45 Y N 
4 25 F Ureteric reflux 28 Living 
Donation 
N/A 2:1:2 Bas + MP Tac + 
MMF 
258 18 N N 
5 78 M Unknown 55 Donation after 
cardiac death 
Intracranial 
haemorrhage 
1:1:1 Bas + MP Tac + 
MMF 
895 30 N N 
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6 52 F Unknown 55 Donation after 
cardiac death 
Intracranial 
haemorrhage 
2:1:1 Bas + MP Tac + 
MMF 
659 30 Y N 
7 65 M Adult polycystic 
kidney disease 
37 Donation after 
cardiac death 
Hypoxic brain 
damage 
1:1:1 Bas + MP Tac + 
MMF 
965 32 Y Y 
8 52 M Adult polycystic 
kidney disease 
37 Donation after 
cardiac death 
Hypoxic brain 
damage 
1:1:0 Bas + MP Tac + 
MMF 
675 33 Y N 
9 24 M Malignant 
hypertension 
42 Living related N/A 1:1:1 Bas + MP Tac + 
MMF 
160 18 N N 
10 53 M Unknown 35 Deceased 
donor 
Intracranial 
haemorrhage 
1:1:0 Bas + MP Tac + 
MMF 
1680 20 N N 
11 42 F Unknown 46 Living  
Related 
N/A 0:2:1 Bas + MP Tac + 
MMF 
212 41 N Y 
12 68 M Hypertension 69 Deceased 
donor 
Road traffic 
accident 
1:1:0 Bas + MP Tac + 
MMF 
802 25 N N 
13 64 M Hypertension 53 Deceased 
donor 
Intracranial 
haemorrhage 
2:1:1 Bas + MP Tac + 
MMF 
1080 35 Y Y 
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14 53 M Hypertension 47 Living related N/A 1:2:1 Alem + 
MP 
Tac + 
MMF 
180 21 N N 
15 51 M Adult polycystic 
kidney disease 
63 Living related N/A 1:2:2 Bas + MP  Tac + 
MMF 
184 36 Y Y 
16 53  M Adult polycystic 
kidney disease 
21 Donation after 
cardiac death 
Subarachnoid 
haemorrhage 
2:1:0 Bas + MP Tac + 
MMF 
870 42 Y N 
17 23  F Renal Tuberculosis 17 Donation after 
cardiac death 
Hypoxic brain 
damage 
1:1:2 Bas + MP Tac + 
MMF 
683 35 Y N 
18 26  M Dysplastic Kidneys 17 Donation after 
cardiac death 
Hypoxic brain 
damage 
1:1:1 Alem + 
MP 
Tac + 
MMF 
952 36 Y N 
19 61 M Adult polycystic 
kidney disease 
48 Deceased 
donor 
Hypoxic brain 
damage 
secondary to 
pulmonary 
embolus 
0:0:0 Bas + MP Tac + 
MMF 
1275 45 Y N 
20 36 M Hypertension 48 Deceased 
donor 
Hypoxic brain 
damage 
0:0:0 Bas + MP Tac + 
MMF 
1090 55 Y N 
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secondary to 
pulmonary 
embolus 
21 63 M Membranous 
nephropathy 
49 Deceased 
donor 
Intracranial 
bleed 
0:0:0 Bas + MP Tac + 
MMF 
816 55 N N 
22 45 M Unknown 43 Living related N/A  Bas + MP Tac , MMF 
+ pred 
42 45 N N 
23 63 M Unknown 45 Living related N/A  Bas + MP Tac + 
MMF 
154 40 N N 
24 29 F Pyelonephritis 38 Deceased 
donor 
Glioma 0:1:0 Bas + MP Tac + 
MMF 
768 25 N N 
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Table 2.2 – Statistical Significance of Recipient and Donor Characteristics  
 AR DGF PF Statistical 
Significance 
Recipient Age 
(years) 
55.5 ± 11 43 ± 14.3 54 ± 20.7 NS 
Sex M/F 3/1 6/2 10/2 NS 
Donor Age 
(years) 
49.8 ± 11 34.3 ± 19.1 49.8 ± 16.6 NS 
Total HLA 
Mismatches 
3.7 ± 1 3.2 ± 0.7 3.1 ± 1 NS 
 
Values = mean ± standard deviation 
NS = Not significant 
2.3 Blood sample collection 
Venous blood was collected in lithium heparinised anticoagulant tubes. The 
blood samples were taken at the same time as routine clinical blood tests. The 
blood was centrifuged at 2000 rpm for ten minutes at 4°C all within one hour of 
sample collection from the patient. The plasma was removed from the sample, 
and stored in Eppendorf tubes at −80°C until NMR measurements were 
performed. In this study plasma was used as the risk of uncontrolled and 
incomplete clotting is very low, allowing excellent reproducibility amongst 
samples.  
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Samples were discarded if contaminated in the blood letting process or were 
delayed by greater than one hour before being frozen. Ethical consideration in 
this study did not allow for a patient to have another blood sample taken solely 
for the study as this would amount to additional intervention in the normal 
clinical care of the patient. 
2.4 NMR sample preparation 
Samples were prepared with a 0.17 % w/v solution of the sodium salt of 3-
(trimethylsilyl)propionic- 2,2,3,3-d4 acid (TSP) (Sigma-Aldrich, UK) in 
deuterium oxide (D2O) (Fluorochem, UK). TSP was used as a chemical shift 
reference (0 ppm). 350 µL of this was added to 300 µL of the plasma in an 
Eppendorf tube. The mixture was vortexed to ensure adequate mixing before 
transferring all 650 µL to a 5 mm NMR tube (528PP-WILMAD, Sigma-Aldrich, 
UK).  
2.5 Preparation of samples for metabolomic analysis of plasma 
Prior to NMR data collection, plasma samples were thawed to room temperature 
and then centrifuged at 4000 rpm for 10 minutes. 
2.6 NMR experiments 
1H-NMR spectra were acquired at 499.97 MHz on a Varian Unity Inova 500 
spectrometer, at 20°C  
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2.6.1 CPMG. 
The Carr-Purcell-Meiboom-Gill (CPMG) pulse sequence [RD – 90° – (τ – 180° – 
τ)n – acq] was used for data collection . This technique removes signals from 
high molecular weight molecules (such as proteins) enabling those for small 
molecules to be resolved and quantified.  A relaxation delay (RD) of 2 seconds 
was used, during which the water resonance was selectively irradiated to 
suppress it. The spin-spin relaxation delay, 2 nτ, of 450 ms was used for all 
samples; τ of 1.5 ms and n of 150. 256 transients were collected into 32,768 data 
points for each spectrum with a spectral width of 6499.84 Hz.  
An exponential line broadening of 1 Hz was applied to each free induction decay 
(FID), prior to zero filling to 65,536 points, followed by Fourier transformation. 
Resultant spectra were phased and baseline corrected using VnmrJ 1.1D (Varian 
Inc., Palo Alto, California, USA).  
2.7 Results 
Spectra were “binned” into 225 segments, each with a width of 0.04 ppm, over 
the range of −1 to 8 ppm. The integrals in each binned segment were measured 
(Turner E, et al., 2007; Turner E, et al., 2008). These relate directly to the 
concentration of the molecules giving rise to the signal. These integrals were 
normalised to unit total sum of the spectral integral to ensure that the spectra 
were directly comparable, and used for multivariate analysis. The chemical shift 
reference molecule, TSP, may also be used as a concentration reference and thus 
for normalisation. However, this charged molecule is known to interact with 
albumin in the plasma, affecting its NMR response. For this reason the 
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alternative approach of normalising to total spectral integral was utilised (Lindon 
JC, et al., 2000; Kriat M, et al.,1992). 
PCA was performed on mean-centred Pareto-scaled data using SIMCA-P + 11 
(Umetrics, Umeå, Sweden). PCA is an unsupervised statistical method able to 
simplify, distinguish and compare between groups of subjects based solely on the 
characteristics of their NMR spectrum, with no knowledge of the ‘preformed’ 
groups (Lindon JC, et al., 2003) and present the data in two or three dimensions.  
Chemical shift ranges δ 4.44 to 5.92 (water) and δ 3.44 to 3.96 (glucose), were 
removed from the analysis of plasma. Lactate found at δ 1.32 to 1.36 (lactate 
methyl (CH3) group) and δ 4.08 to 4.12 (lactate CH2 group) was removed in all 
analyses except as described in section 2.7.4 where lactate was included for 
discrimination purposes. Removal of water was to eliminate the effects of 
varying efficiency in water suppression during NMR data acquisition. It is 
common to remove signals from glucose as these can vary in response to 
differences in the food intake of the individuals’ involved (Holmes E, et al., 
1994). Lactate signals were large and preliminary statistical analyses were 
dominated by these. Whilst Pareto scaling is used to accommodate such wide 
dynamic range within sample metabolite concentrations, it can be beneficial to 
tighten the range (by removing the larger signals) to investigate lower 
concentration components (Turner E, et al., 2007; Tiziani S, et al., 2008). Table 
2.3 shows the common metabolites found in a typical sample of plasma and the 
chemical shift at which it occurs (Nicholson JK et al., 1995). 
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Table 2.3 - Resonance assignments with chemical shifts in spectra of normal 
human blood plasma. 
1H Shift (δ) Multiplicity Molecule 
1.33, 4.11 D(1.33), Q(4.11) Lactate 
1.46 D Alanine 
1.68, 1.91, 3.24 M(1.68, 1.91) T (3.24) Arginine 
1.69 M Lysine 
1.99, 2.05, 2.36, 3.34, 
3.45 
M Proline 
2.52, 2.69 D Citrate 
2.84, 2.94 DD Asparagine 
3.05, 4.05 S Creatinine 
3.06, 3.16 DD Tyrosine 
3.26 S TMAO 
 
Key – S =singlet peak, D = doublet, T = triplet, Q= quartet M = complex 
multiplet, DD= doublet of doublets 
The statistical significance of demographic data was analysed using SPSS v13 
for Windows (SPSS Inc., Chicago, IL), using Kruskall Wallis and Mann-
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Whitney tests. Data was tabulated using Excel (Microsoft ® Excel 2004 for Mac 
2004 .Version 11.0). p values <0.05 were defined as statistically significant.  
Analysis was performed on; 
1. All data for all time points and all patients 
2. With removal of pre-operative, post perfusion and two hour post 
operation samples 
3.  Individual patient sets 
4. Spectra with lactate included 
5. Donor type categories 
 
2.7.1 Analysis of all data for all time points and all patients 
In total, analysis was made of 163 samples, taken pre-operatively, intra-
operatively, two hours post-operatively and on days, 1, 2, 3, 4, 5 and 7. 
Pre-operative samples were taken on admission of the patient for renal transplant 
along with routine pre-operative bloods. Intra-operative blood samples were 
taken one to ten minutes post perfusion of the transplant kidney. The variation in 
time was due to safety and stability of the patient being paramount once 
reperfusion had taken place, so the blood sample was only taken once the patient 
had recovered from the initial insult of reperfusion. Post-operative samples were 
taken two hours after the anaesthesia had been withdrawn. Day one to seven 
bloods were taken early morning with routine samples for clinical practice.   
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Figure 2.1 is a typical output from the PCA of the NMR data. Each point on the 
figure represents an individual time point for an individual patient. The first and 
second principal components PC1, PC2 are depicted; these relate to the two most 
variable bins. Clustering of a majority of samples as shown in figure 2.1 is seen. 
There is no discrimination in terms of metabolite profile between the separate 
clinical groups Metabolic composition analysed by 1H NMR spectroscopy can 
be influenced by lifestyle factors including smoking (Vulimiri SV et al., 2009), 
diet (Holmes E et al., 2008) and medications (Sands CJ, et al., 2009). With this 
in mind, the samples included in the study were reviewed. The pre, intra and 2 
hour post-operative period samples were considered separately (Figure 2.2). 
Within this sample set again no differentiation was seen between those pre, intra 
and two hour postoperative samples. However this series illustrates the natural 
differences between individuals from the outset.  
Pre-operative samples were taken when the patient arrives on the ward for their 
transplant. The very nature of renal transplantation means that patients can turn 
up at anytime of day having eaten, just taken their medications or had a cigarette 
or have been exposed to cigarette smoke. These factors would influence the 
metabolic profiles of the patients rendering spectra difficult to interpret.  
Anesthesia seems to have contributed to the metabolic spectra of blood samples 
taken at the intra-operative and post-operative time points (Figure 2.3). No 
obvious discrimination was seen between the different clinical outcomes at these 
particular time points.  
As it appeared that the pre-operative, intra-operative and 2 hour blood test were 
being effected by pre-operative fasting/non-fasting state, anaesthesia and drugs 
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used at induction, there-by effecting analysis, it was decided to procede to further 
analysis without these three timepoints included in the statistical analaysis.
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∗Acute Rejection 
▼Delayed Graft Function 
ο Primary Function 
PC 1 
PC 2 
Figure 2.1 – Scores plot comparing all data for all time points and all patients 
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∗Acute Rejection 
▼Delayed Graft Function 
ο Primary Function 
PC 1 
PC 2 
Figure 2.2 – Scores plot comparing complete set of plasma for pre-operative, intra-operative and 2 
hours post-operative samples 
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Figure 2.3 – Section of a 1H-NMR spectrum of intra-operative metabolic profile of a plasma sample 
Lipids 
Glucose 
Creatinine 
Lactate 
TMAO 
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2.7.2 Analysis of samples from days one to seven 
In total 117 samples taken on days one, two, three, four, five and seven were 
available for full analysis and comparison.  
The PCA plot shown in figure 2.4 includes all patient plasma samples and shows 
clustering of those patients with acute rejection in the left lower of the scores plot 
(ellipse 1). Also within this area are patients with DGF and a scattering of patient 
with PF. Importantly it is patient samples from days one, two and three in the 
DGF patients found in ellipse 1 but from day four onwards these move trajectory 
to ellipse 2 where a majority of patients with primary function can be found and 
only two plasma samples of a patient with acute rejection; whom incidentally 
was found to have another ongoing pathology related to the kidney (renal vein 
thrombosis) which may account for the differences seen in the metabolic profile 
of this patient. From figure 2.4 no differences in plasma profile can be seen 
between patients with AR or DGF from days one to three, differentiation 
becomes apparent from day four onwards. Figure 2.5 shows on the 1H NMR 
spectrum of plasma of a patient with acute rejection with the magnification of the 
area responsible for differentiation between AR, DGF and PF. Metabolites were 
identified with the aid of reference to a chemical shift database (Nicholson JK et 
al 1995, www.hmdb.ca).  
Figures 2.6 and 2.7 use the same data as in figure 2.4 but concentrate on direct 
comparison of two clinical outcomes not all three. Figure 2.6 compares AR and 
primary function. Whilst there is a small amount of overlap of data, those with 
AR appear in a line, with those with PF moving away from these data points.  
Figure 2.7 compares AR with DGF. Those with AR cluster in the left lower 
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quadrant of the scores plot, with some overlapping of those patients with DGF. 
The plasma samples of those patients with DGF that overlap with those patients 
with AR again echo the finding of figure 2.5 and are the samples taken on days 
one, two and three post-operatively. From day four onwards the metabolic 
profiles of those patients with DGF move away from those samples with AR as 
indicated in the plot. 
The loadings plot (Figure 2.8) identifies regions of the spectrum (ppm/bins) 
giving rise to the discrimination; 3.00 ppm to 3.40 ppm resulting from the 
presence of arginine, trimethylamine-N-oxide (TMAO) and creatinine and 4.00 
to 4.04 ppm (Figure 2.3) also due to creatinine (an additional creatinine signal). 
In days five and seven the metabolic profile of those patients with only DGF and 
no rejection continue to move into the PF group.  
From day one prior to any clinical signs of acute rejection, patients with DGF 
and AR had less intense peaks for arginine and more intense peaks for TMAO 
than those patients with PF. By day 4 arginine peak intensities increase in those 
with only DGF, but remain low in the AR group. DGF patients see a decrease in 
signal intensity for (and thus concentration of) TMAO from day four whilst those 
with AR show a slight increase. 
The statistical significance of the metabolite concentration variations was tested 
using Kruskal–Wallis. Creatinine (3.04 and 4 - 4.04 ppm) was found at a higher 
concentration in the PF compared to either the AR or DGF group (PF versus AR 
p<0.001 and PF versus delayed graft function p=0.079). In the clinical setting 
one would expect the creatinine level to be lower in patients with a primary 
functioning graft. This apparent anomaly may be the result of some DGF and AR 
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patients having undergone dialysis during the study period. The creatinine levels 
would be lowered by this. Trimethylamine-N-oxide (TMAO at 3.27 ppm) was 
responsible for some of the differentiation seen between AR, DGF and PF. 
Statistical significance was almost reached when comparing AR to PF (p=0.068). 
The concentration variation of arginine did not achieve statistical significance.  
Concentration from day three to four when differentiation is seen between AR 
and DGF a 1.53 fold change decrease in the concentration of TMAO in the DGF 
patients versus an increase of 1.26 in the AR group is revealed. A summary of 
fold change of three metabolites contributing to change are shown in table 2.
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∗Acute Rejection 
▼Delayed Graft 
Function 
ο Primary Function 
!
Figure 2.4 - Scores Plot Comparing Acute Rejection, delayed graft function and Primary Function. The direction of the arrow is 
indicative of change in patient metabolic profiles as day’s progress from surgery  
!
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Figure 2.5 1H-NMR spectrum of plasma from patient with acute rejection 
(AR) with expansion of area responsible for differentiation between 
rejected and non-rejected renal transplants 
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∗Acute Rejection 
ο Primary Function 
!
Figure 2.6 Scores Plot Comparing Acute Rejection (AR) 
versus Primary Function (PF)  
!
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Figure 2.7 - Scores Plot Comparing Acute Rejection 
(AR) versus Delayed Graft Function (DGF) 
 
PC 2 
PC 3 
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PC 1 
PC 2 
Figure 2.8 - Loadings Plot. Values furthest from 0 are the greatest cause of discrimination within individual blood samples 
These values correlate with the molecules creatinine, TMAO, and arginine. 
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Table 2.4 - Comparison of concentration fold change from day 3 to day 4 in 
metabolites responsible for discrimination between transplant outcomes 
 
2.7.3 Individual patient sets 
The aim of this analysis was to compare the metabolic profile of individual 
patient sets undergoing renal transplant. All plasma samples taken of patients 
were directly compared to each other to see if there was a trend where-by day 
seven the patient’s metabolic profile returned to their pre-operative sample in 
those patients with PF when compared to those patients who had post-operative 
DGF or AR.  
Figure 2.9 is the scores plot of a patient receiving a live-related renal transplant. 
This patient (patient 11) developed AR as diagnosed on biopsy which was 
successfully treated with methylprednisolone. Analysing the scores plot 
 Primary Function Delayed Graft 
Function 
Acute Rejection 
Trimethylamine-
N-Oxide  
↓  
(0.80) 
↓  
(1.53) 
↑  
(1.26) 
Arginine  ↓  
(0.90) 
↑  
(1.23) 
↑  
(1.17) 
Creatinine  ↓  
(0.95) 
 ↓  
 (1.94) 
↑  
(1.20) 
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unsurprisingly as shown in section 2.7.1 the intra and post-operative samples are 
far removed from the samples taken from day one onwards. Referring to the 
loadings plot (figure 2.10) for differentiation between the samples creatinine and 
β-glucose are contributing to the differences seen between pre-operative, intra-
operative and post-operative samples. Whereas TMAO is found to be 
contributing to the differences seen with samples taken on day three, four and 
five, this is not replicated in the metabolic profile of day seven when AR had 
been proven on biopsy. If this individual plasma set is then compared to another 
patient who underwent a live related renal (LRD) transplant which had primary 
function (patient 9) no obvious trend is apparent, with overlap of samples from 
intra-operative and post-operative to days one through to five. These results are 
in keeping with previous work in this study where those patients with primary 
function have very little difference seen in their metabolic profile from day one 
onwards.   
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Figure 2.9 – Plasma sample of LRD renal transplant 
(Patient 11) 
Pre-op 
Intra-op 
Post-op 
Day 7 
Day 2 
Day 1 
Day 5 
Day 3 
Day 4 
PC 1 
PC 2 
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Figure 2.10 – Loadings plot of plasma samples of patient 11 
PC 1 
PC 2 
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Figure 2.11 – Plasma sample of LRD patient 9 
PC 1 
PC 2 
Pre-op Intra-op 
Post-op 
Day 1 
Day 2 
Day 5 
Day 3 
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Figure 2.12 - Loadings plot of plasma samples of patient 9 PC 1 
PC!2!
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2.7.4 With inclusion of lactate in the spectra 
The aim of this analysis was to observe the role of lactate across the time period 
of blood samples taken in the pre and post-operative period of the renal 
transplant. 
Figure 2.13 shows no statistical differentiation between samples from the three 
different clinical outcomes. When compared on the loadings plot, lactate was 
responsible for the differentiation at ppm 1.32 and 1.36 and also at 4.12 and 4.16, 
but this was regardless of type of donor or clinical outcome. This was felt to be 
due to the large quantity of lactate seen compared to other metabolites, thereby 
dampening down the significance of any of the other metabolites.  
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Figure 2.13 - Comparison of different clinical outcomes with inclusion 
of lactate in metabolic profiles 
PC 1 
PC 2 
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Figure 2.14 – Loadings plot of figure 2.13 PC 1 
PC 2 
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Figure 2.13 - Comparison of different clinical outcomes with inclusion 
of lactate in metabolic profiles 
PC 1 
PC 2 
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Figure 2.14 – Loadings plot of figure 2.13 PC 1 
PC 2 
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2.7.5 Comparison of Different Donor Types  
To assess the reliability of 1H NMR across all modes of transplantation (LRD, 
HB, Non-HB) a direct comparison was made between these different groups. 
Figure 2.13 shows the scores plot in principal components 1 and 2 accounting 
for 82% (R2X 0.826) of the variability in the study population of a direct 
comparison of these transplant types. As can been seen in this figure there is no 
distinguishable difference between the three different group types. This suggests 
that no matter what type of transplantation takes place the metabolic profiles of 
patients in the post-operative period varies depending on transplant outcome not 
on donor type. 
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Figure 2.15 – Direct comparison of LRD, HB and non-HB plasma samples 
     Live Related 
!!!!!!Non-heart beating 
!!!!!!Heart beating 
!
PC 1 
PC 2 
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Chapter 3 
Quantification of Concentration of Plasma  
Metabolites using NMR 
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3.1 Introduction 
To work out the concentration of TMAO present in the plasma samples 
calibration curves using 1H NMR were acquired. In this part of the study 1D 
NMR was used for quantification of metabolite concentration. Whilst the 
benefits of 2D NMR to quantify metabolites have been put forward, it is not 
without its problems (Gronwald W et al., 2008). 1D uses 64k data points but 2D 
only 1k points and therefore has much lower digital resolution meaning the 
signals are not well resolved making interpretation of intensity and baseline noise 
more difficult to resolve. This could prove a problem when interpreting plasma 
samples as the signals for molecules overlap.  
The same high resolution afforded in 1D would be needed with 2D experiments 
but this is not possible in a reasonable time frame, especially with multiple 
samples being analysed. Gronwald et al mentioned the overlap in 2D spectra so 
not all signals could be used for quantification and multidimensional peak 
intensities are influenced by many factors, listed in the paper, meaning 
calibration curves result with very different slopes depending on the signal used, 
hence each signal needs to calibrated individually before achieving an average 
calibration for the metabolite. The lowest concentration of any possible molecule 
to identify will vary depending on the signal to noise ratio. In their study the 
most dilute concentration of 19.5 µM was detected for some metabolites 
including TMAO but the limit of detection for many metabolites was higher. The 
lower limit of quantification as defined by less than 20% relative standard 
deviation from six triplicates was often much higher.  
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For quantification of the TMAO concentration in this study 1D NMR was used 
due to the problems associated with 2D NMR highlighted in the previous 
paragraph. 
3.2 Method 
As TMAO was identified as a potential biomarker of renal transplant AR in 
NMR studies (chapter 2), the same experimental parameters were used in sample 
preparation and pulse sequences to allow for direct relationship with these 
previous samples (sections 2.6 and 2.6.1).  
An aliquot of blood was taken from a control to refine the technique and work 
out the concentrations of TMAO and centrifuged at 4000 rpm for 10 minutes 
before the plasma was aliquotted into 300 µl amounts. The aliquots were stored 
at -80oC for 8 days until the start of the experiment. The maximum time stored at 
4oC between sample make-up and acquisition was 1 hour. Defrosted samples 
were centrifuged at 4000 rpm for 10 minutes and the whole 300 µl added to 
350 µl D2O containing TMAO, then vortexed for approximately 5 seconds and 
650 µl transferred to NMR tubes. All tubes used were of the same specification 
from the same manufacturer.  
Samples were prepared with a 0.17 % w/v solution of the sodium salt of 3-
(trimethylsilyl)propionic- 2,2,3,3-d4 acid (TSP) (Sigma-Aldrich, UK) in 
deuterium oxide (D2O) (Fluorochem, UK). TSP was used as a chemical shift 
reference (0 ppm).  
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Data for all 10 samples containing TMAO were acquired on the same day. Two 
control samples were analysed the following morning using the same preparation 
method.  
To work out the concentration and volumes of TMAO required the following 
methodology was used. 
TMAO Concentration:  
75.11g in 1litre   = 1M  
0.7511g in 1litre  = 10mM 
0.7511g in 100ml  = 100mM 
300µl plasma + 350µl D2O (containing TMAO) = 650µl total volume 
New TMAO concentration = 350 / 650 = 0.538 of original 
Amount of TMAO required relative to original to give same concentration = 1 / 
0.538 = 1.857 
TMAO required = 1.857 x 0.7511g = 1.3949g 
Only 1g TMAO available so 0.6975g in 50ml = 100mM = stock solution 1 
Stock 1 (µl) D2O (µl) Concentration (µM) 
35.00 +  315.00 = 10000 
17.50 + 332.50 = 5000 
8.75 + 341.25 = 2500 
4.38 + 345.62 = 1250 
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and 
10.00 + 990.00 = 1000 = stock solution 2 
Need 625µM so 0.625 x 350 = 218.75 stock solution 2 
Stock 2 (µl) D2O (µl) Concentration (µM) 
218.75 + 131.25 = 625 
109.38 + 240.62 = 312.5 
54.69 + 295.31 = 156.3 
27.34 + 322.66 = 78.1 
13.67 + 336.33 = 39.1 
6.84 + 343.16 = 19.5 
0.00 + 350.00 = 0.0  = control  
3.3 Results 
From early investigation it was clear that the shimming was not as good for the 
very high concentrations, e.g. 10000, 5000 and 2500 µM, but this is likely to be 
due to the sample constitution being changed enormously as these concentrations 
provided gigantic peaks and were far larger than the clinical sample run, typical 
TMAO peaks in the plasma samples of those patients with DGF and AR were 
less than 20 µl. 
This raises the question of sensitivity and accuracy of quantification as these are 
minute changes. The main problem identified when analysing the TMAO peaks 
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which had been spiked with varying concentration of TMAO was the 
overlapping signals found under the TMAO peak.  
With the higher concentration of TMAO in the plasma samples it was hoped that 
there would be a distinct signal from which analysis could take place, however 
the triplet peak of arginine overlapped with the TMAO peak, and deconvolution 
was not possible. Deconvolution is subtraction of an underlying peak from the 
one in question leaving an area that only represents the metabolite of interest. 
This effectively rules out quantification of metabolites using conventional 
techniques as most have some degree of overlap.  
For very high concentrations approximations can be made provided underlying 
peaks are small but this is not scientifically sound as the underlying peak area 
and concentration cannot be accurately determined.  
 
 
!
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Figure 3.1a - Spectra showing TMAO at 3.25ppm with a concentration range 
from 10000 µM to 19.5 µM referenced to lactate at 1.317 ppm. Underlying peaks 
become clear at lower concentrations 
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Arginine!peak!overlapping!TMAO!
peak,!rendering!concentration!
analysis!of!TMAO!not!feasible!
Figure 3.1b & c – Further TMAO peaks. Underlying peaks becoming more 
visible as concentration of TMAO is reduced 
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Figure 3.1d – Spectra with 19.5 µM of TMAO added. Increasing clarity of 
underlying peaks offset by overlapping from Arginine 
Figure 3.1 a-d shows that as the as the intensity of the spectra increases the 
overlapping nature of the arginine triplicate and TMAO peaks become more 
apparent. 
Based on the above experiment quantification of TMAO was not possible. 
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Chapter 4 
Validation 
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4.1 High Performance Liquid Chromatography 
High performance liquid chromatography (HPLC) is a chromatographic 
technique that can separate a mixture of compounds according to their affinity 
for the chromatographic medium to identify, quantify and purify the individual 
components of the mixture (Lough WJ, & Wainer  LW, 1997). 
HPLC operates under high pressure conditions and has two main phases. The 
mobile phase (eluent) is a liquid (a single solvent or mixture of solvents) which is 
moving through the chromatographic column and carrying analytes. The 
stationary phase (adsorbent) is solid porous media which consists of the rigid 
porous particles, usually silica based, with specific surface properties. Differing 
affinities of the mixtures components for the stationary and mobile phases leads 
to their separation, since certain components will be more attracted to the mobile 
phase and will elute quickly whilst others will be retained by the stationary phase 
for longer and therefore will elute more slowly, i.e. have a longer retention time 
(RT) (Allwood JW and Goodacre R., 2010). 
Solvent reservoirs are used, one for each of the mobile phase eluents (solvent A 
and B), as well as further reservoirs for autosampler syringe and line washes. A 
high-pressure pump forms the solvent delivery system, which generates and 
metres a specified flow rate (typically millimetres per min). A solvent 
partitioning valve allows the mixing of solvents A and B at specified ratios and 
time gaps, thus permitting the operator to programme the HPLC to perform 
gradient elution steps (Meyer, 2004). 
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4.2 Method 
In this study the concentration of the amino acids in the plasma was determined 
with reverse phase HPLC in an attempt to identify compounds that overlapped in 
the NMR studies, especially in the region of 3.20 to 3.30 ppm where the 
molecule TMAO is located as well as arginine and choline. σ-phthaldialdehyde 
(OPA) was used as a pre-column derivatising agent, in the presence of a strong 
reducing agent, such as β-mercaptoethanol, reacts rapidly with primary amines to 
form highly fluorescent thio-substituted isoindoles.  
 
 
 
 
Figure 4.1 – Pre-column derivitisation with OPA  
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These can then be separated and analysed by HPLC. 
A Kontron 500 series automated HPLC system fitted with a Jasco fluorescence 
detector, and a 4.5mm Hypersil ODS-16 was used. The system used an 
automated injector, with gradient control, degasser, sample cooler and integrator.  
4.2.1 Solvents A and B 
A solvent system gradient elution programme was run with 18 ml 
tetrahydrofuran, 200 ml methanol and 800 ml sodium acetate as solvent A and 
800 ml methanol and 200 ml sodium acetate as solvent B. 6 M acetic acid was 
used to adjust pH to 5.9. The solution was stored at 4 oC until required. 2 µl β-
mercaptoethanol was added for every 1ml of OPA. The resultant mixture was 
stored in quantities of 1.5 ml at -20 oC until required.  
Table 4.1 – Composition of solvent systems A and B 
 
Component Solvent A (ml) Solvent B (ml) 
83mM Sodium acetate 800 200 
HPLC – grade methanol 200 800 
Tetrahydofuran 10-18* - 
* Tetrahydrofuran was added to buffer A according to chromatogram drift and 
peak separation 
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4.2.2 Reference amino acid composition 
Sigma AA-S-18 amino acid standard solution (alanine, arginine, aspartate, 
glutamate, glycine, histidine, isoleucine, leucine, lysine, methionine, 
phenylalanine, proline, serine, threonine, tyrosine, valine at 2.5 mM and cysteine 
at 1.25 mM) was diluted in a ratio of 1:100 with sterile water to give a final 
concentration of 25 µM for all amino acids, except cysteine which had a final 
concentration of 12.5 µM. The mix (AA-18) was stored at -20 oC until required. 
A second standard mix was made of 4 amino acids (AA-4), 33.02 mg asparagine, 
35.53 mg glutamine, 12.75 mg tryptophan and 15.15 mg cysteine in 100 ml of 
sterile water. This was diluted to give final concentration of 25 µM for 
asparagine, glutamine and tryptophan and 12.5 µM of cysteine. The solution 
(AA-4) was stored at -20 oC until required.  
Prior to use, a standard amino acid solution was made up containing 200 µL of 
AA-18 and 200 µL of AA-4. 25 µL of this standard was aliquoted into 250 µL 
polypropylene HPLC inserts and placed in the loading tray. 
At the start of every new HPLC analysis a standard was run to ensure adequate 
peak separation. A new standard was run every 3 to 7 experimental plasma 
samples. This was performed to ensure quality control and any changes in the 
fluorescence detection of any amino acids over the period of the assays. The 
control samples of amino acids during the analysis allowed for direct comparison 
with plasma samples as analysis took place and account for column changes 
during a certain time period. 
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An analytical run was performed for the designated samples to identify and 
quantify the amino acids within the plasma using 25 µl with an equal volume of 
reagent. Flow rate was maintained at 1.5 ml/min throughout. 
Separation took 34 minutes. Chromatogram peaks were integrated automatically 
by Kontron 2000 software. 
Each individual plasma sample taken from day 1 to 7 was analysed. At this point 
only 89 samples were available for HPLC analysis as all other samples had been 
utilised with the NMR studies. 
4.3 Results  
In total eight amino acids were isolated from a 34 minute HPLC run. The amino 
acids are listed below with associated retention time. 
Aspartate – 5 minutes 
Glutamate – 7 minutes 10 seconds 
Asparagine – 11 minutes 
Histadine – 15 minutes 
Sereine – 19 minutes 
Glutamine – 25 minutes 
Threonine – 26 minutes 
Arginine – 32minutes 
The concentration for each amino acid present was calculated using the 
following formula. 
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From the standard solution we know that the concentration of an amino acid like 
arginine from the area under the curve is equivalent to 10µmmol, the 
concentration of each amino acid from 1µL of plasma in 24µL of water can be 
calculated: 
If the area under the curve is 205.21, this equals 10µmol of arginine. If in the 
plasma sample the area under the curve is 3.22, the concentration of arginine is 
205.21/3.22 =63.72. 10/63.72 =0.156 µmmol of arginine. 
 
To work out concentration in 25µL: 
0.156 x 25 = 3.925µmol of arginine in the plasma. 
 
4.3.1 Univariate Statistics 
Test of normality revealed that data was not normal so ANOVA was not 
applicable. Therefore Kruskal-Wallis test was used for non-parametric data.  
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Table 4.2 - p values for multiple comparisons of amino acids 
Amino&acid& Bonferroni&corrected&p0
value&
Aspartate! 0.168!
Glutamate! 1.000!
Asparagine! 1.000!
Histidine! 0.752!
Serine! 0.224!
Glutamine! 0.224!
Threonine! 0.072!
Arginine! 0.372!
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Figure 4.2 a-h – Box plot analysis of amino acids dependent on clinical outcome 
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(Any outliers are marked with a circle and extreme cases with an asterisk.)  
4.3.2 Multivariate Analysis 
Data is scaled to unit variance in order to ensure that if one amino acid is 
particularly high in concentration compared to others, it does not dominate. 
Figure 4.3 – Scores plot comparing primary function, delayed function and acute 
rejection when comparing Amino acids using HPLC 
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Figure 4.4 – Loadings plot Amino acids responsible for differences seen in 
Figure 4.3 
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Chapter 5 
Discussion 
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Currently only few tests are capable of rapidly assessing the function of a donor 
graft in the immediate post-operative period. The clinical course following renal 
transplantation is varied and early allograft dysfunction can often cause a 
diagnostic dilemma. Definitive diagnosis of AR over other pathology especially 
DGF or CNI toxicity relies on invasive biopsy, which can be complicated by 
haematuria, haematoma, AVM and other injuries often requiring transfusion, re-
exploration or, rarely, graft loss.  The NMR method used in this study uses 
readily available blood samples and requires little or no pre-treatment of the 
sample.  
The importance of early diagnosis of AR at a preclinical level has been shown in 
studies using protocol biopsies (Rush D, et al., 1998; Wilkinson A, et al., 2006). 
Protocol biopsy screening is used to detect subclinical pathologic events, where 
earlier treatment may improve long-term outcome. The idea being that regular 
biopsy in a clinically normal transplant would reveal the pathologic process early 
in its course, allowing time for effective treatment of AR prior to detection with 
traditional methods. The finding of subclinical rejection has been associated with 
decreased graft survival at 10 years, and there is evidence that treatment of 
subclinical rejection improves long-term results. Rush et al. used early 
corticosteroid treatment of patients diagnosed with subclinical rejection based on 
invasive biopsy, even when in the presence of normal serum creatinine. They 
found a decrease in early and late clinical rejection, a lower serum creatinine 
level at twenty-four months and improved long-term graft function (Rush D, et 
al., 1998).  
There is clearly a need for an early non-invasive biomarker of graft function and 
NMR-based metabolomics has the potential to provide this.  
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A similar approach has recently been utilised in liver transplantation although in 
this instance extracts of serum were investigated. A single patient was monitored 
pre-operatively and post-operatively at 3 time points. Different metabolite 
profiles were observed for the first unsuccessful and the second successful liver 
transplants. Lactate, uric acid, glutamine, methionine and citrate were identified 
at different concentrations as early as two hours post operation. The patient’s 
metabolic profile following the successful transplant was found to be comparable 
with that of 5 healthy volunteers two hours post-operation (Serkova NJ, et al., 
2007). 
The targeted profiling of metabolites using 1H-NMR spectroscopy and 
multivariate analysis allowed identification and evaluation of a wide range of 
metabolites in plasma. In section 2.7.2 the results of a metabolome investigation 
involving plasma from 24 patients and samples taken at different time points 
were described. Several molecules were highlighted whose concentration seems 
to reflect the status of the renal graft.  One of these, creatinine, is the breakdown 
product of creatine phosphate. Creatinine levels would usually be expected to 
increase in a non-functioning kidney as in DGF or AR but because of the use of 
dialysis in some of these patients creatinine levels were found to be artificially 
lower. It seems from this current study that whilst creatinine was affected by the 
dialysis, the spectra were not altered in terms of metabolic profile or 
concentration of other metabolites.  
TMAO is an oxidation product of trimethylamine and is found in animals and 
humans (Figure 5.1). TMAO decomposes to TMA, which is the main odorant 
that is characteristic of degrading seafood (Human Metabolome Database). 
TMAO is an osmolyte and acts as a homeostatic agent that the body utilises in  
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Figure 5.1 Chemical structure of TMAO  
 
 
 
 
kidney failure to offset and stabilise the effects of increased concentrations of 
urea, that arise during renal failure or renal stress or in this study with the effects 
of a failing transplant.  TMAO which is secreted from the renal medulla and has 
been correlated with renal injury in the transplant and chronic renal failure 
setting previously when in the presence of a raised urea (Hauet T, et al., 2000; 
Richer J, et al., 2000).  Foxall et al. analysed urine samples with NMR to 
differentiate nephrotoxicity secondary to cyclosporin to those who developed 
AR. For each patient in this study NMR data was compared with clinical 
outcomes, graft biopsy and standard renal blood tests. TMAO was found to be 
significantly increased in urine in patients with AR (Foxall PJ, et al., 1993). The 
study concluded that NMR spectroscopy was useful in this setting and that 
urinary metabolite profiles analysed with NMR can follow the course of renal 
transplant function. Whilst a statistical significance was seen with an increase in 
urinary TMAO in this study in patients with graft dysfunction, it could not 
differentiate entirely those patients with graft dysfunction, normal controls or 
patients with good graft function.  We found TMAO to be elevated in plasma, 
where differentiation in patient groups was seen from day 4 onwards using 
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TMAO as a marker. Le Moyec et al. have also seen these findings on analysis of 
urine and plasma in 39 renal transplant patients (Le Moyec L, et al., 1993). 
TMAO should not usually appear in the plasma of a healthy individual as it is 
effectively filtered by the healthy kidney (Bell JD, et al., 1991). Bell et al. in 
their study of 16 plasma and urine samples in 16 chronic renal failure patients 
showed that TMAO was closely correlated with rising urea and creatinine, a 
similar process in those patients with non-functioning renal transplant. Results 
from this study show to almost statistical significance that changes in TMAO 
concentration are associated with AR and DGF as diagnosed on biopsy with no 
evidence of CNI toxicity. The studies performed so far that have observed a rise 
in TMAO (urinary) in the dysfunctioning kidney, whether as a renal transplant or 
in the chronic failure group, however they have concluded that the sensitivity and 
specificity are not good enough for clinical diagnosis. 
Arginine arises in the urea cycle and its pathway is altered in chronic renal 
failure where patients with little normal functional renal mass see a reduction in 
arginine (Tizianello A, et al., 1980). In transplantation changes in arginine 
production may be due to the ischaemia/reperfusion injury associated with 
transplant (Becker T, et al., 2009). Arginine deficiency could develop because of 
decreased arginine output from the proximal tubules of the kidney; these provide 
the major endogenous supply throughout the body (Wu G & Morris SM, 1998) 
and may be affected by AR or DGF. When interpreting the NMR results initial 
arginine concentration in the PF group is high and concentration levels change 
little over the separate time points of this study. This differs from the AR group 
where levels start low and remain low for the duration of the study. Change is 
seen in the DGF group where initial low levels of arginine start to increase the 
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further out from the operation the patient is, resembling the PF group. However 
in the NMR spectrum TMAO and arginine appear at similar positions and further 
tests were required to differentiate between the two metabolites. Validation was 
performed utilizing HPLC (Chapter 4) and has shown that changes in arginine is 
not significant across differing renal transplant outcomes (p=0.372). No other 
metabolite using the HPLC method in this study revealed any metabolite 
contributing to discrimination between the differing types of graft outcome. 
The key to our findings is the stage at which it is possible to discriminate 
amongst the groups and the implications this could have for clinical practice. 
Based on our results treatment could have been initiated for the AR group a 
minimum of 48 hours earlier than is the norm with currently used tests. Earlier 
treatment of AR would allow for better long-term outcomes, additionally it could 
be argued that in those patients with only DGF who underwent biopsy, this was 
an unnecessary invasive and potentially transplant threatening procedure. A non-
invasive plasma biomarker that suggests DGF in a non-functioning graft may 
instill confidence in the clinician to “sit tight” for a further 24 to 48 hours and 
wait to see if the renal transplant starts clearing on its own. The biomarkers 
identified could have established those patients with DGF who will not go onto 
develop AR and those with DGF who will go onto develop AR, from day 4 and 
thus avoid unnecessary biopsies.  
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In summary we have demonstrated, using high resolution 1H-NMR spectroscopy 
of plasma, coupled with multivariate statistical analysis, early discrimination in 
metabolic profiles of patients with DGF, AR and PF in the renal transplant 
setting. 
Our data shows: 
• Metabolic profiles from day 4 can differentiate between AR and DGF 
• Metabolic profiles of those with PF differ from day 1 compared to those 
with AR or DGF 
• Patients with PF who then develop AR have profiles different to those 
with PF alone from day 1 
• Those with DGF who then develop AR have metabolic profiles the same 
as those who just have AR  
 
Whilst we may be some time from these tests being performed in the transplant 
outpatient setting, our data from 24 patients with 6 separate post-operative time 
points are encouraging. NMR spectroscopy could become a technique for 
discrimination of graft outcome in the renal transplant setting without any 
disadvantage to the patient. From a practical stand point this method allows 
analysis of plasma by a non-destructive process enabling identification of 
TMAO, amino acids and other small molecules all at the same time facilitating 
identification of novel biomarkers for graft outcome.  
Future work in this field would be necessary before any clinical application could 
be utilized from the findings here. There would need to be an increase in number 
of patients analysed and the methods performed in other laboratories. 
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 Patient information leaflet, consent form and letter to General Practionner 
A Study to Identify Early Markers for Delayed Graft 
Function and Transplant Rejection 
 
You have been invited today to participate in a study looking into ways of detecting why 
some transplants take longer to start working and ways of detecting transplant rejection 
earlier than the current methods. The hope being that earlier detection may mean quicker 
treatment of the problem and therefore improve the outcome for the patient and their 
transplant. 
Thank you for considering participation in this study. You are under absolutely NO 
obligation to take part and if you chose not to take part your medical management will in 
no way be effected. 
Please read this leaflet carefully and at your own leisure, feel free to discuss it with 
friends and family, your GP or consultant. 
What is the Study About? 
You may be aware that by having a liver or kidney transplant one of the risks associated 
with this is rejection or delayed working. This is where your body fights against the 
transplant that they have been given. Rejection and delayed function can be difficult to 
diagnose and other conditions (e.g. infection) can often present like rejection. There is no 
one test that can diagnose rejection. Our aim is to try and find a substance in blood that 
might predict transplant rejection. 
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Why Me? 
As you are going ahead to receive a liver or kidney transplant you are an ideal person for 
this study. 
Who is Organising the Study? 
The study will be taking place at St James’s University Hospital with the help of The 
University of Leeds under the guidance of the Liver and Kidney Unit. Mr R Prasad and 
Mr N Ahmad are the two lead consultants with an interest in this topic. The research 
fellow is Mr Paul Goldsmith who will be spending 2 years on this topic with the aim of 
achieving a research qualification. 
How will it Affect Me? 
If you agree to take part you will be required to sign a consent from to say that you are 
happy to go ahead. The study will NOT require you to visit hospital more regularly and 
your hospital stay will hardly be any different than if you didn’t take part. On the day you 
arrive to hospital for your transplant a single sample of 4mls of blood will be taken along 
with your other routine blood tests so you won’t need an extra blood test. During your 
operation again another sample of blood will be taken whilst you are asleep. After the 
operation a sample of blood will need to be taken at 2, 24 and 48 hours and then on days 
3, 4, 5 and 7. All these blood tests will be taken along with other routine blood tests. In 
some instances the post operative blood sample may require an extra blood test.  
What Will Happen to the Blood Samples? 
With the blood samples tests will be carried out in the laboratory looking for any signs 
that might predict transplant rejection.   
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At the end of the study that will take a total of 2 years all samples will be destroyed. 
Are There Any Risks? 
There are no risks in taking part. You should not notice anything different in your 
management as blood tests are often a routine part of treatment, but by being in this study 
some of you blood once taken will be analysed for any signs that may predict rejection or 
delayed functioning of your transplant. 
Are There any Benefits? 
You will not benefit from the study but it is hoped that a few years down the line patients 
in a similar position to you will. 
Is The Study Confidential? 
At no time will your name appear on blood samples, just your date of birth and unit 
number. A letter of confirmation would be sent to your GP and consultant so that they are 
aware that you wish to participate in the study. 
Final Outcome 
If it is ok with you, once the study is finished a letter will be sent to your home address 
telling you of how the study went and if any break through in has been made. 
You are under absolutely no obligation to take part in this study and if you have 
any questions please feel free to email me at goldsmithpaul@hotmail.com or phone 
in office hours to 07787 113 150 which are the details of the doctor running the 
study. 
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Patient Consent Form 
 
A Study to Identify Early Markers for Delayed Graft 
Function and Transplant Rejection 
 
Name 
Date of Birth 
Unit Number 
Study Number 
Consultant 
 
Please initial the boxes once you are satisfied to take part in the study  
 
• I have read the patient information leaflet   
 
• I have had the opportunity to discuss the study 
with family, friends, GP or consultant 
 
• I understand the purpose of the study and how  
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I am involved 
 
• I understand by taking part in this study I  
will not gain any direct personal gain 
 
• I understand that all information collected  will be   
confidential 
 
• I confirm that I am happy to take part in the is study  
of my own free will and can withdraw at any time I wish. 
It will not have any effect on my medical management 
 
I agree to take part in the study: 
Signed………………………………………. Date………..   
   
Print………………………………………….. 
 
Person Taking Consent………………………    Date……… 
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Dear Dr GP 
Your patient is about to undergo a liver/kidney transplant and has kindly agreed to 
participate in a trial looking at biomarkers for delayed graft function and acute transplant 
rejection. As you may be aware the diagnosis of delayed graft function and acute 
rejection is often difficult to make and no-one test can make a definite diagnosis. 
 
The trial involves taking a sample of blood preoperatively, perioperatively and samples at 
2, 24 and 48 hours, day 3,4,5, and 7 postoperatively. The samples will be then 
centrifuged and stored at -800C until analysis at The Leeds University Chemistry 
Laboratories. At this point the plasma will be placed in a spectrometer where an 
electromagnetic pulse will be fired at the samples. The end product is a spectrum 
identifying all metabolites within the sample.  
 
These spectra will be analysed and the metabolites compared. We will then look at the 
progress the patients make on the ward and in the outpatient setting during routine follow 
up. It is hoped that the spectra may reveal differing metabolic intensities in those patients 
who go onto graft dysfunction or acute rejection. 
The study will not alter patient management. 
If you have any questions please don’t hesitate to contact me on 07787113150 or email at 
goldsmithpaul@hotmail.com and I will help as best I can with any further enquiries. 
 
Kind Regards 
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Paul Goldsmith 
Research Fellow 
St James’s University Hospital 
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